HM Payson & Co’s Alexion Pharmaceuticals ALXN Stock Holding History

HM Payson & Co’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-11	Closed	-$2K	–	1153
2021 Q2	$2K	Hold	11	–	–	﹤0.01%	1029
2021 Q1	$2K	Buy	+11	New	+$1.7K	﹤0.01%	1077

Other funds holding ALXN

Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return

Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

HM Payson & Co's ALXN Position: Q3 2021 in Review

HM Payson & Co sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 11 shares — an estimated $2K sold.

HM Payson & Co first reported a position in ALXN in Q1 2021 and held it in 2 quarters. The position peaked at $2K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

HM Payson & Co reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
HM Payson & Co sold 11 Alexion Pharmaceuticals shares in Q3 2021, an estimated $2K.
HM Payson & Co first reported a position in Alexion Pharmaceuticals in Q1 2021 and held it in 2 quarters.
HM Payson & Co's Alexion Pharmaceuticals position peaked at $2K in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on HM Payson & Co's 13F filing for Q3 2021, filed 30 Nov 2021.